News coverage about Auris Medical Holding AG (NASDAQ:EARS) has been trending positive on Wednesday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Auris Medical Holding AG earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.6866796170998 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

EARS has been the topic of a number of recent research reports. ValuEngine lowered shares of Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research raised shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research report on Wednesday, August 30th. Finally, Roth Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Auris Medical Holding AG in a research report on Saturday, July 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $3.25.

Shares of Auris Medical Holding AG (NASDAQ:EARS) traded down 0.139% during midday trading on Wednesday, reaching $0.719. 232,835 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $0.73 and a 200 day moving average price of $0.75. Auris Medical Holding AG has a 12 month low of $0.60 and a 12 month high of $1.80. The company’s market cap is $31.87 million.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.09. Equities research analysts forecast that Auris Medical Holding AG will post ($0.63) earnings per share for the current fiscal year.

WARNING: “Positive Media Coverage Somewhat Unlikely to Affect Auris Medical Holding AG (EARS) Share Price” was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/13/positive-media-coverage-somewhat-unlikely-to-affect-auris-medical-holding-ag-ears-share-price.html.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical Holding AG (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.